Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Advani, R. H., Flinn, I., Popplewell, L., Forero-Torres, A., Bartlett, N. L., Ghosh, N., Kline, J., Tran, T., Lynn, J., Chen, J. Y., Agoram, B., Huang, J., Takimoto, C. M., Chao, M., Smith, S. M. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.7504

View details for Web of Science ID 000442916002575